GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial.

Autor: Strambu IR; Pulmonology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.; Joint first authors., Seemayer CA; Clinical Development, Galapagos GmbH, Basel, Switzerland Christian.Seemayer@glpg.com.; Joint first authors., Fagard LMA; Clinical Development, Galapagos NV, Mechelen, Belgium., Ford PA; Clinical Development, Galapagos NV, Mechelen, Belgium., Van der Aa TAK; Clinical Development, Galapagos NV, Mechelen, Belgium., de Haas-Amatsaleh AA; Clinical Development, Galapagos NV, Mechelen, Belgium., Modgill V; Clinical Development, Galapagos GmbH, Basel, Switzerland., Santermans E; Clinical Development, Galapagos NV, Mechelen, Belgium., Sondag EN; Early Stage Development, Galapagos NV, Mechelen, Belgium., Helmer EG; Clinical Development, Galapagos Biotech Limited, Cambridge, UK., Maher TM; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.; National Heart and Lung Institute, Imperial College London, London, UK., Costabel U; Department of Pneumology, Ruhrlandklinik University Hospital, University of Duisburg-Essen, Essen, Germany., Cottin V; National Coordinating Reference Center for Rare Pulmonary Diseases (OrphaLung), Louis Pradel Hospital, Hospices Civils de Lyon, University of Lyon, IVPC, INRAE, Member of ERN-LUNG, Lyon, France.

Publikováno v: The European respiratory journal [Eur Respir J] 2023 Mar 02; Vol. 61 (3). Date of Electronic Publication: 2023 Mar 02 (Print Publication: 2023).